Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Inventory (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Change in Inventory for 10 consecutive years, with $14.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 96.77% year-over-year to $14.2 million, compared with a TTM value of $31.1 million through Dec 2025, up 181.01%, and an annual FY2025 reading of $31.1 million, up 181.01% over the prior year.
  • Change in Inventory was $14.2 million for Q4 2025 at Heron Therapeutics, up from -$2.9 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $16.0 million in Q2 2025 and bottomed at -$9.1 million in Q3 2022.
  • Average Change in Inventory over 5 years is $2.1 million, with a median of $557500.0 recorded in 2021.
  • The sharpest move saw Change in Inventory tumbled 599.46% in 2022, then surged 6900.0% in 2024.
  • Year by year, Change in Inventory stood at $6.9 million in 2021, then tumbled by 66.08% to $2.3 million in 2022, then plummeted by 95.59% to $103000.0 in 2023, then soared by 6900.0% to $7.2 million in 2024, then soared by 96.77% to $14.2 million in 2025.
  • Business Quant data shows Change in Inventory for HRTX at $14.2 million in Q4 2025, -$2.9 million in Q3 2025, and $16.0 million in Q2 2025.